14 Day Bismuth Quadruple: U.S. H. pylori Treatment After ACG Update
Optimized bismuth quadruple therapy for 14 days is now the preferred first-line treatment for H. pylori infection. Alternatives include rifabutin triple therapy, vonoprazan-based dual or triple regimens, and FDA-approved combination products such as Talicia, Voquezna, and Pylera. Whichever regimen you use, completing the full course and confirming eradication with proper test-of-cure timing matter as much as the drug choice itself.
TL;DR: Bismuth quadruple therapy for 14 days remains the preferred first-line treatment, especially when antibiotic susceptibility is unknown or resistance is suspected. Resistance to clarithromycin and levofloxacin has significantly increased, lowering the effectiveness of traditional triple therapies and emphasizing the need for susceptibility testing. Regimens like rifabutin triple therapy and vonoprazan-based therapies are reserved for cases with prior treatment failure, resistance, or penicillin allergy. Confirming eradication with noninvasive tests at least four weeks after treatment completion is crucial for accurate assessment. Adherence strategies, such as using pill organizers and clear dosing schedules, help improve treatment success and reduce failure due to missed doses.
Precision Digestive HealthGet Specialist H. pylori CareDr. Meet Parikh provides specialized gastroenterology care for digestive health concerns, including diagnosis, treatment, and ongoing management.Schedule an appointment
Table of Contents
- First-line and alternative H. pylori treatment options
- Why antibiotic resistance changed the guidelines
- How to choose the right regimen for your situation
- Managing side effects and staying on track with treatment
- Confirming your infection is actually gone
- Notes from clinical practice on tailoring treatment
- Why these guideline changes matter for you
- Getting tested and treated with a specialist
- Sources
- FAQ
First-line and alternative H. pylori treatment options
The 2024 ACG guideline names optimized bismuth quadruple therapy (BQT) as the preferred first-line regimen for patients who have not been treated before. It pairs a proton pump inhibitor with bismuth subsalicylate or subcitrate, tetracycline, and metronidazole, taken for 14 days. The guideline favors this combination empirically, without needing to know the specific antibiotic susceptibility of the infecting strain, because resistance to metronidazole can often be overcome by bismuth’s direct antibacterial action and the regimen’s extended duration.
Rifabutin triple therapy is one alternative, delivered commercially as Talicia. Its FDA label specifies four capsules of omeprazole, amoxicillin, and rifabutin taken three times daily with food for 14 days. Because rifabutin resistance in H. pylori remains uncommon, this option is useful when other antibiotic classes are compromised, though it carries a rare but notable myelotoxicity warning.
Vonoprazan-based regimens use a potassium-competitive acid blocker instead of a traditional PPI. The Voquezna prescribing information outlines two versions: Voquezna Triple Pak combines vonoprazan, amoxicillin, and clarithromycin twice daily for 14 days; the Dual Pak contains vonoprazan and amoxicillin at recommended dosings for 14 days, excluding clarithromycin.
Pylera combines bismuth subcitrate, metronidazole, and tetracycline capsules taken four times daily, paired with a twice-daily PPI for 10 days, shorter than the 14-day duration often preferred for other bismuth quadruple regimens.
Choosing between these options often comes down to practical factors:
- Pill burden: BQT and Pylera require multiple capsules several times a day, which can challenge adherence.
- Penicillin allergy: True allergy rules out amoxicillin-containing regimens like Talicia and Voquezna Triple or Dual Pak, but BQT does not depend on amoxicillin.
- Prior antibiotic exposure: Previous clarithromycin or metronidazole use raises the chance those drugs will fail again.
Why antibiotic resistance changed the guidelines
Rising resistance to clarithromycin and levofloxacin is the main reason empiric clarithromycin triple therapy fell out of favor. A peer-reviewed review of antimicrobial resistance in H. pylori describes sharp increases in resistance to both drugs in recent years, which undermines regimens that depend on them working.
Susceptibility-guided therapy outperforms empiric treatment in meta-analyses, with eradication rates around 85% versus roughly 75% for empiric regimens, according to the same review. That gap explains why guidelines now discourage empiric clarithromycin triple therapy unless susceptibility has been confirmed.
Testing options include:
- Culture-based susceptibility testing, which requires endoscopic biopsy and specialized lab processing, limiting its everyday availability.
- Molecular stool or biopsy tests, which detect resistance mutations faster but are not universally accessible.
- Empiric selection, the practical default when testing is unavailable, favoring regimens like BQT that do not depend on clarithromycin susceptibility.
How to choose the right regimen for your situation
- Ask about prior antibiotic use. Previous macrolide exposure (for sinus infections, pneumonia, or prior H. pylori attempts) raises the odds of clarithromycin resistance.
- Confirm penicillin allergy status. A verified allergy history, rather than an assumed one, determines whether amoxicillin-based options are safe.
- Default to optimized BQT when susceptibility is unknown. It works regardless of clarithromycin resistance status.
- Consider clarithromycin triple therapy only with confirmed susceptibility. Without testing, this combination carries a higher failure risk.
- Reserve rifabutin or vonoprazan-based regimens for specific scenarios, such as prior treatment failure, documented resistance patterns, or penicillin allergy after BQT has already failed.
Pro Tip: Bring a list of every antibiotic you have taken in the past two years to your appointment. It helps your clinician avoid a drug your infection may already resist.
Managing side effects and staying on track with treatment
Missed doses are the most common reason H. pylori treatment fails, and 14-day regimens with three or four daily doses make that easy to happen. Bismuth quadruple therapy can cause dark stools, metallic taste, and mild nausea. Rifabutin carries a rare risk of low white blood cell counts, so unexplained fever or unusual bruising during treatment warrants a call to your clinician. Vonoprazan and PPI-based regimens are generally well tolerated but can still cause diarrhea or headache.
- Use a pill organizer or phone alarms tied to meals, since several regimens require dosing with food.
- Write out the full schedule, including which pills pair with which meals, before starting.
- Call your clinician promptly for severe diarrhea, signs of allergic reaction, or symptoms that worsen rather than improve.
Pro Tip: Ask your pharmacist to write the dosing schedule directly on the bottle label. It removes the guesswork that often derails complex regimens.
Confirming your infection is actually gone
Test-of-cure should happen no sooner than 4 weeks after finishing antibiotics, and you need to stop PPIs or potassium-competitive acid blockers for at least 2 weeks beforehand, according to ACG guideline commentary on testing timing. Testing too early or while still on acid-suppressing medication risks a false negative.
- Urea breath test or stool antigen test are the preferred, noninvasive options for most patients.
- Endoscopic biopsy-based testing is reserved for patients who need endoscopy anyway, such as those with alarm symptoms or ulcer follow-up.
- If the infection persists, the next regimen should avoid any antibiotic class used in the failed attempt, and susceptibility testing becomes more valuable at this stage.
You can read more about choosing the right test for H. pylori and about the safety questions around stopping long-term PPI use before testing.
Notes from clinical practice on tailoring treatment
Tracking local eradication outcomes helps a practice know whether its default empiric regimen is still performing at an acceptable level, and shifting strategy when it is not. Patients labeled “penicillin-allergic” often have not had a formal allergy evaluation, and confirming that history can reopen access to amoxicillin-containing regimens, which are central to several of the highest-performing options.
Most H. pylori treatment failures trace back to incomplete courses or repeating an antibiotic the infection already resists, not to a lack of effective drugs.
Brief counseling on dosing schedules, expected side effects, and the exact test-of-cure window is one of the simplest ways to raise completion rates and catch treatment failure early.
Why these guideline changes matter for you
Rising resistance made old assumptions about clarithromycin triple therapy unreliable, but the shift toward optimized bismuth quadruple therapy and newer FDA-approved options has kept cure rates high for patients who complete treatment and get retested. Most H. pylori infections are curable with the right regimen and follow-up. Talk with your clinician about which option fits your allergy history, prior antibiotic use, and tolerance for pill burden.
— Precision Digestive Health
Getting tested and treated with a specialist
Choosing the right H. pylori regimen depends on details a quick online search cannot resolve: your prior antibiotic history, allergy status, and whether biopsy-based testing makes sense for your case. Diagnostic testing options may include urea breath and stool antigen testing, upper endoscopy when biopsy or culture is indicated, and tailored treatment plans with structured post-treatment confirmation.
If an infection has not responded to a prior course of antibiotics, or the case involves allergies or other complicating factors, a gastroenterologist can help sort through the options. Explore our services or schedule a consultation to get a treatment plan built around your history rather than a generic protocol.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- ACG Guideline on Treatment of Helicobacter pylori: New Recommendations… Will Practice Change? - American College of Gastroenterology
- TALICIA prescribing information (highlights) - FDA
FAQ
What happens if H. pylori doesn’t go away with antibiotics?
Persistent infection after treatment usually means the antibiotic regimen encountered a resistant strain or the course was not completed as prescribed. Your clinician will typically select a rescue regimen that avoids any antibiotic class used in the failed attempt, and susceptibility testing becomes more useful at this stage if it is available.
What triggers H. pylori infection?
H. pylori spreads primarily through direct contact with saliva, vomit, or stool from an infected person, often within households, and through contaminated food or water in areas with limited sanitation. Once established in the stomach lining, the bacteria can persist for years without treatment.
What foods should I avoid if I have H. pylori?
There is no specific diet proven to eradicate H. pylori, but avoiding foods that worsen stomach irritation, such as spicy, fatty, or highly acidic items, along with alcohol and caffeine, can ease symptoms during treatment. Following your prescribed antibiotic regimen remains the actual path to eradication.
What is the most effective treatment for H. pylori?
Optimized bismuth quadruple therapy for 14 days is the preferred first-line treatment because it works effectively regardless of clarithromycin resistance status. Rifabutin triple therapy and vonoprazan-based regimens are reasonable alternatives depending on allergy history and prior antibiotic exposure.
